{
    "clinical_study": {
        "@rank": "19929", 
        "arm_group": [
            {
                "arm_group_label": "Desvenlafaxine + Omega 3 FA supplement", 
                "arm_group_type": "Experimental", 
                "description": "Desvenlafaxine 50mg/day & Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period"
            }, 
            {
                "arm_group_label": "Desvenlafaxine + Placebo (for Omega 3 FA supplement)", 
                "arm_group_type": "Active Comparator", 
                "description": "Desvenlafaxine 50mg/day & Placebo (for Omega 3 FA supplement) over a 12 week period"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine\n      (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety\n      symptoms in patients with select medical conditions (cancer, cardiovascular diseases and\n      diabetes)."
        }, 
        "brief_title": "Omega 3 FA Supplements as Augmentation in the Treatment of Depression", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Major Depression", 
            "Cancer", 
            "Diabetes", 
            "Cardiovascular Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Depression", 
                "Depressive Disorder", 
                "Diabetes Mellitus", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or older\n\n          -  Diagnosed with depression and have cardiovascular disease, diabetes or cancer.\n\n          -  Able to provide written informed consent prior to initiation of any study-related\n             procedures.\n\n          -  Able to understand and comply with the requirements of the study.\n\n        Exclusion Criteria:\n\n          -  Hospitalized patients or psychotherapy for depression begun within 4 weeks.\n\n          -  Patients with medically reversible causes of depression (e.g. hypothyroidism).\n\n          -  Patients with significant comorbid symptoms (e.g. pain, insomnia) that have a direct\n             causal relation to depressive and anxiety symptoms with these comorbid symptoms\n             dominating the clinical scenario. Patients will be enrolled in the study if these\n             comorbid symptoms merely coexist with depressive and anxiety symptoms and are not\n             dominating the clinical scenario as judged by the study investigator\n\n          -  Patients with an identifiable diagnosis of substance abuse or dependence within 6\n             months prior to evaluation (except those in full remission, or those with caffeine or\n             nicotine dependence) as defined by DSM-IV criteria.\n\n          -  Patients with any clinically significant unstable or inadequately treated co-morbid\n             medical condition which, in the opinion of the investigator, would make the patient\n             unsuited for the study\n\n          -  Patients with currently active or with significant history of other clinically\n             significant psychiatric disorders such as bipolar disorder, schizophrenia etc.\n\n          -  Pregnant patients, breastfeeding or those planning to become pregnant during the\n             study.\n\n          -  Any other condition, which, in the opinion of the investigator, would make the\n             patient, unsuited for enrollment in the study, including known or suspect history of\n             allergy to fish oil, fish or desvenlafaxine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01803711", 
            "org_study_id": "OmegaDVS"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Desvenlafaxine + Omega 3 FA supplement", 
                    "Desvenlafaxine + Placebo (for Omega 3 FA supplement)"
                ], 
                "intervention_name": "Desvenlafaxine", 
                "intervention_type": "Drug", 
                "other_name": "Pristiq"
            }, 
            {
                "arm_group_label": "Desvenlafaxine + Omega 3 FA supplement", 
                "intervention_name": "Omega 3 Fatty acids", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Desvenlafaxine + Placebo (for Omega 3 FA supplement)", 
                "intervention_name": "Placebo (for Omega 3 fatty acid supplement)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "O-desmethylvenlafaxine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Omega 3 fatty acid", 
            "Fish oil", 
            "Depression", 
            "cancer", 
            "diabetes", 
            "high blood pressure", 
            "cardiovascular"
        ], 
        "lastchanged_date": "March 1, 2013", 
        "location": {
            "contact": {
                "email": "jkamath@uchc.edu", 
                "last_name": "Jayesh Kamath, MD PhD", 
                "phone": "860-679-6727"
            }, 
            "contact_backup": {
                "email": "oodesina@uchc.edu", 
                "last_name": "Oluwanisola Odesina", 
                "phone": "860-679-8931"
            }, 
            "facility": {
                "address": {
                    "city": "Farmington", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06030"
                }, 
                "name": "University of Connecticut Health Center"
            }, 
            "investigator": {
                "last_name": "Jayesh Kamath, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness.", 
        "overall_contact": {
            "email": "jkamath@uchc.edu", 
            "last_name": "Jayesh Kamath, MD PhD", 
            "phone": "860-679-6727"
        }, 
        "overall_contact_backup": {
            "email": "oodesina@uchc.edu", 
            "last_name": "Oluwanisola Odesina", 
            "phone": "860-679-8931"
        }, 
        "overall_official": {
            "affiliation": "University of Connecticut Health Center", 
            "last_name": "Jayesh Kamath, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Hospital Anxiety and Depression Scale", 
            "safety_issue": "No", 
            "time_frame": "12 weeks from baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01803711"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Montgomery-Asberg depression rating scale (MADRS).", 
                "safety_issue": "No", 
                "time_frame": "12 weeks from baseline"
            }, 
            {
                "measure": "short form health survey (SF-12)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks from baseline"
            }, 
            {
                "measure": "visual analog scale for energy (VAS-E)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks from baseline"
            }, 
            {
                "measure": "visual analog scale for pain (VAS-P)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks from baseline"
            }, 
            {
                "measure": "Leeds sleep evaluation questionnaire (LSEQ)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks from baseline"
            }
        ], 
        "source": "University of Connecticut Health Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Connecticut Health Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}